ZMapp: Additional Phase I/II data

Additional data from the open-label, international Phase I/II PREVAIL II trial in 71 patients with Ebola virus infection showed that 50 mg/kg IV ZMapp every 3 days plus standard of care (SOC) led to 28-day mortality rates in patients treated in Guinea (n=12) and in patients treated in the U.S., Liberia and Sierra Leone (n=59) of 14.3% and 24.1%, respectively, vs. 40% and 36.7% for SOC alone. In patients ages <18 (n=23) and >=18 (n=48), ZMapp plus SOC led to 28-day mortality rates of 20% and 23.8%, respectively, vs. 50% and 33.3% for SOC alone. SOC included aggressive fluid resuscitation, hemodynamic support and other interventions available in an optimized care setting. Data were published in The New England Journal of Medicine. NIH’s National Institute of Allergy and Infectious Diseases (NIAID) sponsored the trial in partnership with local governments, the Institut National de la Sante et de la Recherche Medicale (INSERM) and other agencies...